Project Grant R01CA294653
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$429K
Federal Agency
National Cancer Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $667,118.00 to The Regents of the University of California, San Francisco to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The 5-year project, beginning on April 1, 2025, will systematically analyze pancreatic cancer cell lysosomes to identify key proteins that enable pro-survival catabolic...
This Project Grant award of $1,396,152.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to examine the role of the protein BNIP3 and mitophagy (selective degradation of mitochondria) in muscle atrophy during cancer cachexia associated with pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse models of PDAC to investigate how BNIP3 promotes atrophy of muscle fibers by reducing mitochondrial mass, and how reconstitution...
This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
The National Cancer Institute (NCI) awarded a $159,540 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of North Carolina at Chapel Hill. The grant supports research to mechanistically examine and inhibitor target nutrient scavenging processes, including macropinocytosis and autophagy, for the treatment of pancreatic cancer. The research aims to understand how inhibitors of the KRAS-ERK MAPK pathway regulate these metabolic processes over time, and...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to conduct research aimed at advancing cancer screening, diagnostic technologies, and early detection methodologies. The project, titled "Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia", will focus on reversing cachexia (severe muscle wasting) induced by pancreatic ductal adenocarcinoma...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $103,948 to Wayne State University to investigate the role of the Ran guanine exchange factor, RCC1, in pancreatic ductal adenocarcinoma (PDAC) progression. The objectives are to study how RCC1 impacts PDAC metabolic activity and mRNA processing, as well as examine the effects of RCC1 overexpression on PDAC development and metastasis using animal models. The award period runs...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $268,345 to the Sanford Burnham Prebys Medical Discovery Institute to develop a novel immunotherapy for pancreatic cancer. The goal is to investigate the therapeutic potential of blocking the PSGL-1/VISTA axis, which regulates T cell function, to enhance the immune response against pancreatic tumors. The research will explore the impact of PSGL-1 blockade alone and in combination with...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $145,000.00 in funding to the University of Oklahoma Health Sciences Center to investigate the role of the JMJD4 enzyme in pancreatic cancer. The research aims to determine how JMJD4 affects the growth and invasiveness of pancreatic tumor cells, as well as its potential mechanisms of action through modulating transcription factors NRF2 and HIF-2A. This work is expected to advance...
This $128,199 Project Grant, awarded on August 14, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower), supports research to determine the role of the lipid kinase PIKFYVE in regulating metabolic homeostasis in pancreatic ductal adenocarcinoma (PDAC) and explore the synergistic effects of inhibiting PIKFYVE and the KRAS-MAPK signaling pathway. The research aims to delineate the functional relationship between PIKFYVE and lipid homeostasis in PDAC, establish a rationale...
This $351,131 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Miami to mechanistically dissect the signaling interactions between myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs) that contribute to chemotherapy and immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). The goal is to uncover novel insights into the tumor-permissive and tolerogenic role of...